Todd Lehman Joins LumaBridge as Vice President and Head of Business Development

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, May 31, 2023
Information
Tags: 
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PPD, Business development, Laboratory, Medical Affairs Bureau, University, Clinical trial, Thermo Fisher Scientific, Biomedical engineering, Alcon, Chemical engineering, Ophthalmology, Growth, Therapy, Fine chemical
Geotags: 
UNITED STATES, NORTH AMERICA, TEXAS
Organisation: 
LUMABRIDGE
Summary
Key Points: 
  • LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
  • Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge.
  • "We are thrilled to welcome Todd to the LumaBridge team," said David Boyle, Chief Executive Officer of LumaBridge.
  • “I’m honored to be joining LumaBridge at this exciting stage of growth in the company’s evolution,” said Todd Lehman.


LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.

Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge. His expertise spans multiple therapeutic areas, with a particular emphasis on oncology and ophthalmology. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer at PPD, a Thermo Fisher Scientific company. Prior to PPD, he led the Medical Affairs, Global Clinical & Regulatory Operations at Alcon Laboratories. Todd began his career in the clinical research industry in 2004 at Rx Development Resources, the CRO division of Sirion Therapeutics. Todd holds an M.S. in biomedical engineering and a B.S. in chemical engineering, from the University of South Florida.

"We are thrilled to welcome Todd to the LumaBridge team," said David Boyle, Chief Executive Officer of LumaBridge. "Todd's extensive experience in the industry will play a pivotal role in driving our next phase of growth as we continue to scale our clinical trial capabilities."

“I’m honored to be joining LumaBridge at this exciting stage of growth in the company’s evolution,” said Todd Lehman. “I look forward to supporting the continued efforts of our customers in bringing innovative solutions to oncology patients.”

About LumaBridge

LumaBridge is a specialty clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharma companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial guidance, strategic partnership, and personalized attention to each sponsor, accelerating the development of potential therapies.

LumaBridge builds on the success and experience of a seasoned team, led by Dr. George Peoples, to support drug development, accelerating therapies to patients and guiding biopharma companies through clinical and regulatory pathways. As part of their comprehensive CRO services, LumaBridge offers consultation on trial design and clinical development strategy.

For more information, visit lumabridge.com.

Copyright: 
Copyright Business Wire 2023